Also: the state of AAV vectors in gene therapy, and potentially better AI in drug discovery
(Temple Health, 9/3/19)
Temple University researchers may have identified a new target for treating Alzheimer’s. Their research suggests that mitochondrial calcium transport remodeling, a cellular process that is meant to compensate for cellular deficiencies caused by the disease, eventually contributes to patient decline. If this process does indeed contribute to Alzheimer’s symptoms, it could also offer a new therapeutic target for further research.
(Julianna LeMieux, Genetic Engineering and Biotechnology News, 9/3/19)
Genetic therapy researchers are getting excited about the possible applications of adeno-associated viruses (AAVs) to deliver gene therapies. The article briefly discusses the history of gene therapies before moving on to recent advances like newly approved AAV drugs, possible roadblocks for viral vectors in gene therapy, and AAV manufacturing.
(University of Cambridge, 9/3/19)
University of Cambridge researchers have published two articles claiming that they have developed an algorithm that can predict complex chemical reactions better than chemists, and that can also suggest compounds and reactions to reach a desired chemical product. These two tasks are crucial to early drug development and could help expedite early drug discovery.
—Stories compiled by Senior Scientific Writer Mary Parker